Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ebastine as Adjuvant Therapy in Tumor Budding-Positive Hepatocellular Carcinoma
NCT07734766Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- Oct 2026
- Primary completion
- Mar 2029
01
Overview
Phase 4, open-label, single-arm trial of eribulin in hepatocellular carcinoma (HCC), sponsored by Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: 1-Year Recurrence-Free Survival Rate. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
eribulin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07734766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07734766.